Nurix Therapeutics (NRIX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- $5.11
- Surprise
- —
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Stock Market: Will S&P 500 Open Up or Down Today? — benzinga, 2026-10-08
- Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leuk — benzinga, 2026-10-07
Where TrendMatrix's rating stands now
TrendMatrix currently rates NRIX Sell at 4.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Pipeline: bexobrutideg
- Quality below floor (1.8 < 4.0)
- Momentum score 4.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $22.21
- Price target
- $29.52
- Stop
- $20.90
- Upside to target
- +32.9%
- Reward-to-risk
- 3.8:1
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-09 — shown for context, not personalized investment advice.
NRIX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.30B
- P/E (fwd)
- -20.8
- 52-week range
- $9.00–$28.23
- Off 52-week high
- 21.3%
- RSI (14)
- 20
- Volume vs avg
- 1.47×
- Score today
- 4.9/10